Spun out of Bausch Health Companies (formerly Valeant), Bausch + Lomb (BLCO) offers a portfolio of well-known brands encompassing over 400 lens care, pharmaceutical, and surgical equipment and products, serving the $50 billion eye health market in over 100 countries. The company believes its history of innovation and broad portfolio has enabled it to build brand loyalty and serve as a trusted partner for both consumers and healthcare professionals across the entire eye health spectrum. Since 2018, Bausch + Lomb has invested over $2 billion in building out its infrastructure and advancing its pipeline, including investing in high-growth premium products. Coupled with M&A, the company believes this will position it well to accelerate growth and drive margin expansion.
For the five other things you need to know about Bausch + Lomb ahead of its IPO, sign up for a free trial of IPO Pro.
